ACE |
Angiotensin-converting enzyme |
AD |
Alzheimer’s disease |
AESI |
Adverse events of special interest |
AGS |
Aicardi–Goutières syndrome |
AMI |
Acute myocardial infarction |
AMI I/R injury |
AMI ischemia–reperfusion injury |
ARDS |
Acute respiratory distress syndrome |
ASC |
Apoptosis-associated speck-like protein containing a CARD |
ATF4 |
Activated parkin via protein kinase RNA-like endoplasmic reticulum kinase-activating transcription factor 4 |
BDNF |
Brain-derived neurotrophic factor |
BiPAP |
Bilevel positive airway pressure |
BV-2 |
A type of microglial cell derived from C57/BL6 mice |
CAPS |
Cryopyrin-associated periodic syndromes |
CARD |
Caspase activation and recruitment domain |
CCNE2 |
Essential for the control of the cell cycle at the late G1 and early S phases; belongs to the cyclin family |
CCR2 |
C–C motif chemokine receptor 2 |
CH |
Clonal hematopoiesis, hematopoietic stem and progenitor cells |
CI |
Confidence interval |
CK-MB |
Creatine kinase-MB fraction |
COPD |
Chronic obstructive pulmonary disease |
COX-2 |
Cyclooxygenase 2 |
CRP |
C-reactive protein |
CRS |
Cytokine release syndrome |
Cyclin E2 |
Cyclin E2 is a protein that in humans is encoded by the CCNE2 gene |
DDS |
4,4′-Diaminodiphenyl sulfone (dapsone) |
DIC |
Disseminated intravascular coagulation |
ECG |
Electrocardiogram |
G6PDH |
Glucose-6-phosphate dehydrogenase |
HLA |
Human leukocyte antigen |
HLA-DRB1 |
Major histocompatibility complex, class II, DR beta 1 |
ICU |
Intensive care unit |
IFN |
Interferon |
IFNAR2 |
Interferon-alpha and beta receptor subunit 2 |
IL |
Interleukin |
IL-1β |
Interleukin-1 beta |
IMV |
intensive mechanical ventilation |
IRF3 |
Interferon regulatory factor 3 |
JNK |
Jun N-terminal kinases |
LDH |
Lactate dehydrogenase |
LDL |
Low-density lipoprotein |
LL |
Lepromatous leprosy |
MADDS |
Monoacetyldapsone |
MAPK |
Mitogen-activated protein kinase |
MCI |
Mild cognitive impairment |
MHC |
Major histocompatibility complex |
MIS-C/A |
Multisystem inflammation syndrome in children and adults |
MPO |
Myeloperoxidase |
NOD2 |
Nucleotide-binding oligomerization domain containing 2 |
mRNA |
Messenger RNA |
mtDNA |
Mitochondrial DNA |
NACHT |
Domain conserved in NAIP, CIITA, HET-E, and TP1 |
NF-κB |
nuclear factor kappa-light-chain-enhancer of activated B cells |
NLRP3 |
NOD-, LRR-, and pyrin domain-containing protein 3 |
PAI-1 |
Plasminogen activator inhibitor-1 |
PAMPs |
Pathogen-associated molecular patterns |
PBMCs |
Human peripheral blood mononuclear cells |
PD |
Parkinson’s disease |
PEDF |
Pigment epithelium-derived factor |
PEDFR/iPLA2 |
PEDF/calcium-independent phospholipase A2 |
Phospho-p65 |
Anti-phospho-NFkB p65 (Ser536) monoclonal antibody (T.849.2) |
Phospho-IκBα |
Phospho-IκBα (Ser32/36) (5A5) mouse mAb #9246 |
PTGS2 |
Prostaglandin synthase 2 |
PTM |
Multiple post-translational modification |
ROS |
Reactive oxygen species |
S |
Full-length prefusion spike glycoprotein of SARS-CoV-2 |
S1 |
SARS-CoV-2 spike protein subunit 1 |
SCLS |
Systemic capillary leak syndrome |
RCT |
Randomized controlled trial |
SOD |
Superoxide dismutase |
TGF-β |
Transforming growth factor-beta |
THP-1 |
A spontaneously immortalized monocyte-like cell line |
TNF |
Tumor necrosis factor |
TLR |
Toll-like receptor |
TMPRSS2 |
Transmembrane protease serine subtype 2 |
TTS |
Thrombosis with thrombocytopenia syndrome |
TYK2 |
Tyrosine kinase 2 |